GRG Health captured real-world insights from 100 neurologists, geriatricians, and psychiatrists across Malaysia, Thailand, Taiwan, Indonesia, and the Philippines. The study uncovered critical gaps in diagnostic infrastructure, disparities in treatment access, and varying levels of readiness for DMT adoption. These insights are already enabling smarter launch planning and earlier stakeholder engagement for Alzheimer’s therapies in the region.
Summary
Summary:
Discover how GRG Health assessed regional market readiness for Alzheimer’s Disease treatments across 5 Asian countries and why it matters for future DMT launches.
A leading healthcare intelligence initiative set out to evaluate how ready Southeast Asian markets are to adopt next-generation Alzheimer’s Disease therapies.
The challenge? Fragmented healthcare systems, varied reimbursement models, and limited diagnostic infrastructure across the region.
Using a focused, AI-supported quantitative approach, the study delivered:
✅ Insights from 100 Alzheimer’s-treating specialists across 5 countries in <2 weeks
✅90%+ physicians rely on generics like donepezil and memantine
✅72% aware of global DMT approvals, but 60% concerned about affordability and infrastructure
✅Taiwan and Malaysia show highest likelihood of DMT adoption
✅Major barriers include lack of PET/MRI, weak reimbursement frameworks, and caregiver stigma
This case study enabled early market shaping, guided policy engagement strategies, and helped define launch priorities for DMTs in Asia.
Interested in knowing more? Fill out the form to download the case study and see how GRG Health helps life sciences stay ahead of the curve.
Meet the Author
